更新于：2024-12-17
Betamethasone Sodium Phosphate
磷酸钠倍他米松
更新于：2024-12-17
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C22H30FNa2O8P |
InChIKeyODEOTKLZVXBMJD-LWCNAHDDSA-N |
CAS号151-73-5 |
关联
18
项与 磷酸钠倍他米松 相关的临床试验Efficacy of Intramuscular Glucocorticoid Injection in Patients With Lumbar Radicular Pain
Preemptive Infiltration With Betamethasone and Ropivacaine for Postoperative Pain in Laminoplasty or Laminectomy (PRE-EASE)
Timing of Late Preterm Corticosteroid Administration and Neonatal Hypoglycemia
100 项与 磷酸钠倍他米松 相关的临床结果
登录后查看更多信息
100 项与 磷酸钠倍他米松 相关的转化医学
登录后查看更多信息
100 项与 磷酸钠倍他米松 相关的专利（医药）
登录后查看更多信息
426
项与 磷酸钠倍他米松 相关的文献（医药）2025-02-01CARBOHYDRATE POLYMERS
Intervention mechanism of amphiphilic natural sweeteners on starch chain dynamic behavior: Computational and experimental insights
Article
作者: Lu, Baiyi ; Wang, Fan ; Shen, Jianfu
Amphiphilic natural sweeteners (i.e. steviol glycosides (STE) and glycyrrhizic acid (GA)) have been adopted to improve the quality of various starchy products, which can fundamentally be characterized as the intervention of the former in the chain dynamic behavior of the latter. However, these phenomena and related mechanisms still lack systematic insights. Herein, dual-temperature molecular dynamic simulations combined with experimental analysis were used to tandemly investigate the intervention of sweeteners in six types of chain dynamic behaviors that are strongly correlated with starch properties, including unwinding, movement, long/short-term reassociation, rearrangement, and depolymerization. The results show that STE and GA both promoted the chain unwinding and movement, and also retarded the chain short/long-term reassociation and rearrangement. Besides, GA exhibited a greater role than STE in facilitating chain unwinding and movement. Peculiarly, GA (0 %-40 % w/w) collaborated with starch to form a new microstructure, especially at high content (≥ 20 % w/w), which endowed starch with exceptionally high hardness (15.50 gf→189.36 gf) and hardening rate (2.72 gf/d→17.76 gf/d), and also placed a physical barrier to retard starch depolymerization (slowly digestible starch: 11.26 %→20.62 %). This work contributes data and theoretical support for the development of starch/amphiphilic natural sweetener composite matrices.
2024-11-01Pain Physician
A Randomized Double-blind Trial of 5% Dextrose Versus Corticosteroid Hydrodissection for Meralgia Paresthetica.
Article
作者: Zhu, Jiaan ; Shi, Xiaochen ; Bai, Ling ; Xu, Hailin ; Li, Guicheng
BACKGROUND:
Ultrasound-guided 5% dextrose (D5W) hydrodissection provides favorable outcomes for treating peripheral entrapment neuropathies; its safety is well recognized. However, clinical evidence regarding the use of D5W hydrodissection for meralgia paresthetica (MP) is limited. Although corticosteroids are the most common injectates, the possible adverse effects are a big concern.
OBJECTIVE:
To compare the efficacy and safety of ultrasound-guided D5W hydrodissection compared to corticosteroid hydrodissection in patients with MP during a 6-month follow-up period.
STUDY DESIGN:
A prospective, randomized double-blind, controlled trial.
SETTING:
Outpatient clinic at a university hospital.
METHODS:
A total of 56 patients with MP were randomly allocated to either a D5W or steroid group in a 1:1 ratio. The patients received one session of ultrasound-guided perineural injection therapy of 10 mL D5W or a corticosteroid solution (1 mL compound betamethasone [1 mL: betamethasone sodium phosphate 5 mg and betamethasone dipropionate 2 mg] mixed with 5 mL 2% lidocaine and 4 mL 0.9% saline).The primary outcomes were Visual Analog Scale (VAS) scores for MP (pain and paresthesia) and global quality of life. The secondary outcomes included self-reported successful clinical response and injection adverse effects. Evaluations were conducted at pretreatment and at one, 3, 4 and 6 months posttreatment.
RESULTS:
All patients completed the study. Compared with baseline, both groups exhibited reductions in VAS scores for MP and global quality of life at all follow-up time points, with statistical differences at 3, 4, and 6 months in the D5W group (P < 0.05), as well as those at one, 3, and 4 months in the steroid group (P < 0.05). The D5W group exhibited greater improvement than the steroid group in VAS scores for MP and global quality of life at 4 and 6 months (P < 0.05), and demostrated a more successful clinical response at 6 months (P < 0.05). No adverse effects were reported in the D5W group during the study period, while 6 patients in the steroid group reported an adverse effect.
LIMITATIONS:
A longer follow-up period is necessary; the exact mechanism of D5W is not clear.
CONCLUSIONS:
Ultrasound-guided perineural injection therapy of D5W is more beneficial than corticosteroid injection for MP at 4 to 6 months posttreatment. Additionally, D5W displays a better safety profile than corticosteroid. Thus, we suggest D5W as a more suitable injectate for patients with MP.
2024-10-01JOURNAL OF CONTROLLED RELEASE
Reprogramming monocytes into M2 macrophages as living drug depots to enhance treatment of myocardial ischemia-reperfusion injury
Article
作者: Zhang, Zongquan ; Liu, Yan ; Xu, Maochang ; Jiang, Jun ; Li, Chunhong ; Deng, Yiping ; Zhou, Xiangyu ; Zhang, Yingying ; Zhou, Meiling ; Wang, Xueqin
Delivering therapeutic agents efficiently to inflamed regions remains an intractable challenge following myocardial ischemia-reperfusion injury (MI/RI) due to the transient nature of the enhanced permeability and retention effect, which disappears after 24 h. Leveraging the inflammation-homing and plasticity properties of circulating monocytes (MN) as hitchhiking carriers and further inducing their polarization into anti-inflammatory phenotype macrophages upon reaching the inflamed sites is beneficial for MI/RI therapy. Herein, DSS/PB@BSP nanoparticles capable of clearing reactive oxygen species and inhibiting inflammation were developed by employing hollow Prussian blue nanoparticles (PB) as carriers to encapsulate betamethasone sodium phosphate (BSP) and further modified with dextran sulfate sodium (DSS), a targeting ligand for the scavenger receptor on MN. This formulation was internalized into MN as living cell drug depots, reprogramming them into anti-inflammation type macrophages to inhibit inflammation. In vitro assessments revealed the successful construction of the nanoparticle. In a murine MI/RI model, circulating MN laden with these nanoparticles significantly enhanced drug delivery and accumulation at the cardiac injury site, exhibiting favorable therapeutic ability and promoting M2-biased differentiation. Our study provides an effective approach with minimally invasion and biosecurity that makes this nanoplatform as a promising candidate for immunotherapy and clinical translation in the treatment of MI/RI.
100 项与 磷酸钠倍他米松 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 溃疡性结肠炎 | 日本 | 1992-03-13 | |
| 克罗恩病 | 日本 | 1992-03-13 | |
| 睑缘炎 | 日本 | 1985-11-20 | |
| 结膜炎 | 日本 | 1985-11-20 | |
| 角膜炎 | 日本 | 1985-11-20 | |
| 耳炎 | 日本 | 1985-11-20 | |
| 炎症 | 美国 | 1974-12-31 | |
| 胶原蛋白疾病 | 日本 | 1973-01-31 | |
| 内分泌系统疾病 | 日本 | 1973-01-31 | |
| 心脏衰竭 | 日本 | 1973-01-31 | |
| 肾病综合征 | 日本 | 1973-01-31 | |
| 类风湿关节炎 | 日本 | 1973-01-31 | |
| 眼部炎症 | 日本 | 1964-10-07 | |
| 外耳炎 | 日本 | 1964-10-07 | |
| 中耳炎 | 日本 | 1964-10-07 | |
| 过敏性鼻炎 | 日本 | 1964-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 1 | (Bupivacaine Hydrochloride and Betamethasone Sodium Phosphate) | 繭醖壓蓋簾襯製鬱鬱築(鹹遞醖蓋遞膚糧壓窪壓) = 築齋願築鹹願鏇遞餘蓋 衊範糧繭築鏇積簾簾獵 (鏇餘醖構製齋廠鏇積襯, 簾廠遞廠壓餘鏇餘繭鏇 ~ 範遞廠鹹壓醖憲艱衊獵) 更多 | - | 2020-11-02 | ||
(Bupivacaine Hydrochloride) | 繭醖壓蓋簾襯製鬱鬱築(鹹遞醖蓋遞膚糧壓窪壓) = 齋觸繭積窪遞顧顧築淵 衊範糧繭築鏇積簾簾獵 (鏇餘醖構製齋廠鏇積襯, 齋廠餘鑰鬱壓艱糧構鹹 ~ 願顧襯蓋蓋製選鬱鹹範) 更多 | ||||||
N/A | 糖尿病 blood glucose levels | 5 | 繭簾鹽獵窪廠獵衊積簾(衊顧築製網艱醖製鏇鹹) = 鑰廠選積鬱範獵鹹顧淵 鹽顧憲壓顧鑰蓋築網顧 (獵網繭積壓壓齋壓構淵 ) | 积极 | 2009-06-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用